Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 389, Issue 8, 2016, Pages 831-838

  Shirakura, Takashi ^a   Nomura, Johji ^a   Matsui, Chieko ^a   Kobayashi, Tsunefumi ^a   Tamura, Mizuho ^a   Masuzaki, Hiroaki ^b  

^a TEIJIN PHARMA LIMITED   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Endothelial dysfunction; Febuxostat; Hypertension; Xanthine oxidase

Indexed keywords

3 NITROTYROSINE; FEBUXOSTAT; NITROPRUSSIDE SODIUM; URIC ACID; XANTHINE OXIDASE; 3-NITROTYROSINE; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; ENZYME INHIBITOR; TYROSINE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; HYPERTENSION; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; VASODILATATION; WISTAR KYOTO RAT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; TIME FACTOR; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOMARKERS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEBUXOSTAT; HYPERTENSION; MALE; OXIDATIVE STRESS; RATS, INBRED SHR; RATS, INBRED WKY; TIME FACTORS; TYROSINE; VASODILATION; VASODILATOR AGENTS; XANTHINE OXIDASE;

EID: 84969752623     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-016-1239-1     Document Type: Article

References (61)

1. Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA, Tousson A, Gladwin MT, Patel RP, Tarpey MM, Batinic-Haberle I, White CR, Freeman BA (2001) Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A 98:15215–15220. doi:10.1073/pnas.221292098
2. Augustin AJ, Boker T, Blumenroder SH, Lutz J, Spitznas M (1994) Free radical scavenging and antioxidant activity of allopurinol and oxypurinol in experimental lens-induced uveitis. Invest Ophthalmol Vis Sci 35:3897–3904
3. Bannasch D, Safra N, Young A, Karmi N, Schaible RS, Ling GV (2008) Mutations in the SLC2A9 gene cause hyperuricosuria and hyperuricemia in the dog. PLoS Genet 4:e1000246
4. Boban M, Kocic G, Radenkovic S, Pavlovic R, Cvetkovic T, Deljanin-Ilic M, Ilic S, Bobana MD, Djindjic B, Stojanovic D, Sokolovic D, Jevtovic-Stoimenov T (2014) Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease. Ren Fail 36:613–618
5. Boon CM, Ng MH, Choo YM, Mok SL (2013) Super, red palm and palm oleins improve the blood pressure, heart size, aortic media thickness and lipid profile in spontaneously hypertensive rats. PLoS One 8, e55908. doi:10.1371/journal.pone.0055908
6. Boueiz A, Damarla M, Hassoun PM (2008) Xanthine oxidoreductase in respiratory and cardiovascular disorders. Am J Physiol Lung Cell Mol Physiol 294:L830–840. doi:10.1152/ajplung.00007.2008
7. Ceriello A (2008) Possible role of oxidative stress in the pathogenesis of hypertension. Diabetes Care 31(Suppl 2):S181–184. doi:10.2337/dc08-s245
8. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ (2008) Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension 52:818–827. doi:10.1161/HYPERTENSIONAHA.108.113357
9. Dopp JM, Philippi NR, Marcus NJ, Olson EB, Bird CE, Moran JJ, Mueller SW, Morgan BJ (2011) Xanthine oxidase inhibition attenuates endothelial dysfunction caused by chronic intermittent hypoxia in rats. Respir Int Rev Thorac Dis 82:458–467
10. Durante P, Chavez M, Perez M, Romero F, Rivera F (2010) Effect of uric acid on hypertension progression in spontaneously hypertensive rats. Life Sci 86:957–964. doi:10.1016/j.lfs.2010.05.004
11. Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA J Am Med Assoc 300:924–932. doi:10.1001/jama.300.8.924
12. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q, Taylor WR, Harrison DG, de Leon H, Wilcox JN, Griendling KK (1997) p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80:45–51
13. Galbusera C, Orth P, Fedida D, Spector T (2006) Superoxide radical production by allopurinol and xanthine oxidase. Biochem Pharmacol 71:1747–1752. doi:10.1016/j.bcp.2006.02.008
14. George J, Carr E, Davies J, Belch JJ, Struthers A (2006) High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114:2508–2516
15. Grayson PC, Kim SY, LaValley M, Choi HK (2011) Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res 63:102–110. doi:10.1002/acr.20344
16. Grossman E (2008) Does increased oxidative stress cause hypertension? Diabetes Care 31(Suppl 2):S185–189. doi:10.2337/dc08-s246
17. Harrison R (2002) Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med 33:774–797
18. Horiuchi H, Ota M, Kobayashi M, Kaneko H, Kasahara Y, Nishimura S, Kondo S, Komoriya K (1999) A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats. Res Commun Mol Pathol Pharmacol 104:307–319
19. Houston M, Estevez A, Chumley P, Aslan M, Marklund S, Parks DA, Freeman BA (1999) Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem 274:4985–4994
20. Isa M, Hayashi G, Kowa Y (1968) Effects of xanthine oxidase inhibitor, 4-hydroxypyrazolo-(3, 4-d)-pyrimidine(zyloric) on the nucleic acid metabolism and its pharmacological actions. 1. Nihon Yakurigaku Zasshi 64:108–122
21. Kelley EE, Trostchansky A, Rubbo H, Freeman BA, Radi R, Tarpey MM (2004) Binding of xanthine oxidase to glycosaminoglycans limits inhibition by oxypurinol. J Biol Chem 279:37231–37234. doi:10.1074/jbc.M402077200
22. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA (1999) Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension 33:1353–1358
23. Krishnan E, Kwoh CK, Schumacher HR, Kuller L (2007) Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 49:298–303. doi:10.1161/01.HYP.0000254480.64564.b6
24. Laakso J, Mervaala E, Himberg JJ, Teravainen TL, Karppanen H, Vapaatalo H, Lapatto R (1998) Increased kidney xanthine oxidoreductase activity in salt-induced experimental hypertension. Hypertension 32:902–906
25. Laakso JT, Teravainen TL, Martelin E, Vaskonen T, Lapatto R (2004) Renal xanthine oxidoreductase activity during development of hypertension in spontaneously hypertensive rats. J Hypertens 22:1333–1340
26. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG (2003) Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111:1201–1209. doi:10.1172/JCI14172
27. Li H, Horke S, Forstermann U (2013) Oxidative stress in vascular disease and its pharmacological prevention. Trends Pharmacol Sci 34:313–319
28. Liu W, Wang W, Song SW, Gu XF, Ma XJ, Su FY, Zhang H, Liu AJ, Su DF (2011) Synergism of telmisartan and amlodipine on blood pressure reduction and cardiorenal protection in hypertensive rats. J Cardiovasc Pharmacol 57:308–316. doi:10.1097/FJC.0b013e3182073e41
29. Lockette W, Otsuka Y, Carretero O (1986) The loss of endothelium-dependent vascular relaxation in hypertension. Hypertension 8:II61–66
30. Malik UZ, Hundley NJ, Romero G, Radi R, Freeman BA, Tarpey MM, Kelley EE (2011) Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. Free Radic Biol Med 51:179–184. doi:10.1016/j.freeradbiomed.2011.04.004
31. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38:1101–1106
32. Morawietz H, Weber M, Rueckschloss U, Lauer N, Hacker A, Kojda G (2001) Upregulation of vascular NAD(P)H oxidase subunit gp91phox and impairment of the nitric oxide signal transduction pathway in hypertension. Biochem Biophys Res Commun 285:1130–1135. doi:10.1006/bbrc.2001.5312
33. Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J, Johnson RJ (2003) Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 23:2–7
34. Nickenig G, Harrison DG (2002) The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 105:393–396
35. Oda M, Satta Y, Takenaka O, Takahata N (2002) Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 19:640–653
36. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF (2003) An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 278:1848–1855. doi:10.1074/jbc.M208307200
37. Ong SL, Vickers JJ, Zhang Y, McKenzie KU, Walsh CE, Whitworth JA (2007) Role of xanthine oxidase in dexamethasone-induced hypertension in rats. Clin Exp Pharmacol Physiol 34:517–519. doi:10.1111/j.1440-1681.2007.04605.x
38. Pacher P, Liaudet L, Mabley J, Komjati K, Szabo C (2002a) Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol 40:1006–1016
39. Pacher P, Mabley JG, Soriano FG, Liaudet L, Komjati K, Szabo C (2002b) Endothelial dysfunction in aging animals: the role of poly(ADP-ribose) polymerase activation. Br J Pharmacol 135:1347–1350. doi:10.1038/sj.bjp.0704627
40. Pacher P, Schulz R, Liaudet L, Szabo C (2005) Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 26:302–310. doi:10.1016/j.tips.2005.04.003
41. Radi R, Rubbo H, Bush K, Freeman BA (1997) Xanthine oxidase binding to glycosaminoglycans: kinetics and superoxide dismutase interactions of immobilized xanthine oxidase-heparin complexes. Arch Biochem Biophys 339:125–135. doi:10.1006/abbi.1996.9844
42. Sanchez-Lozada LG, Tapia E, Bautista-Garcia P, Soto V, Avila-Casado C, Vega-Campos IP, Nakagawa T, Zhao L, Franco M, Johnson RJ (2008a) Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Ren Physiol 294:F710–718. doi:10.1152/ajprenal.00454.2007
43. Sanchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Zhao L, Johnson RJ (2008b) Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol, Dial, Transplant Off Publ Eur Dial Transplant Assoc Eur Ren Assoc 23:1179–1185. doi:10.1093/ndt/gfm783
44. Schroder K, Vecchione C, Jung O, Schreiber JG, Shiri-Sverdlov R, van Gorp PJ, Busse R, Brandes RP (2006) Xanthine oxidase inhibitor tungsten prevents the development of atherosclerosis in ApoE knockout mice fed a Western-type diet. Free Radic Biol Med 41:1353–1360
45. Sundstrom J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan RS (2005) Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 45:28–33. doi:10.1161/01.HYP.0000150784.92944.9a
46. Szabo C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, Soriano FG, Van Duzer JH, Williams W, Salzman AL, Groves JT (2002a) Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 8:571–580
47. Szabo C, Zanchi A, Komjati K, Pacher P, Krolewski AS, Quist WC, LoGerfo FW, Horton ES, Veves A (2002b) Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 106:2680–2686
48. Szabo C, Pacher P, Zsengeller Z, Vaslin A, Komjati K, Benko R, Chen M, Mabley JG, Kollai M (2004) Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol Med 10:28–35
49. Tan S, McAdams M, Royall J, Freeman BA, Parks DA (1998) Endothelial injury from a circulating mediator following rat liver ischemia. Free Radic Biol Med 24:427–434
50. Tanito M, Nakamura H, Kwon YW, Teratani A, Masutani H, Shioji K, Kishimoto C, Ohira A, Horie R, Yodoi J (2004) Enhanced oxidative stress and impaired thioredoxin expression in spontaneously hypertensive rats. Antioxid Redox Signal 6:89–97. doi:10.1089/152308604771978381
51. Tian N, Thrasher KD, Gundy PD, Hughson MD, Manning RD Jr (2005) Antioxidant treatment prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Hypertension 45:934–939. doi:10.1161/01.HYP.0000160404.08866.5a
52. Touyz RM (2004) Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 44:248–252. doi:10.1161/01.HYP.0000138070.47616.9d
53. Trachtman H, Valderrama E, Futterweit S (1991) Nephrotoxicity of allopurinol is enhanced in experimental hypertension. Hypertension 17:194–202
54. Trujillo M, Alvarez MN, Peluffo G, Freeman BA, Radi R (1998) Xanthine oxidase-mediated decomposition of S-nitrosothiols. J Biol Chem 273:7828–7834
55. Ungvari Z, Gupte SA, Recchia FA, Batkai S, Pacher P (2005) Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 3:221–229
56. Viel EC, Benkirane K, Javeshghani D, Touyz RM, Schiffrin EL (2008) Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 295:H281–288. doi:10.1152/ajpheart.00304.2008
57. Yamamoto Y, Ogino K, Igawa G, Matsuura T, Kaetsu Y, Sugihara S, Matsubara K, Miake J, Hamada T, Yoshida A, Igawa O, Yamamoto T, Shigemasa C, Hisatome I (2006) Allopurinol reduces neointimal hyperplasia in the carotid artery ligation model in spontaneously hypertensive rats. Hypertens Res Off J Jpn Soc Hypertens 29:915–921. doi:10.1291/hypres.29.915
58. Yiginer O, Ozcelik F, Inanc T, Aparci M, Ozmen N, Cingozbay BY, Kardesoglu E, Suleymanoglu S, Sener G, Cebeci BS (2008) Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol Off J Ger Card Soc 97:334–340
59. Yokoyama Y, Beckman JS, Beckman TK, Wheat JK, Cash TG, Freeman BA, Parks DA (1990) Circulating xanthine oxidase: potential mediator of ischemic injury. Am J Phys 258:G564–570
60. Zhang Y, Chan MM, Andrews MC, Mori TA, Croft KD, McKenzie KU, Schyvens CG, Whitworth JA (2005) Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat. Am J Hypertens 18:910–916. doi:10.1016/j.amjhyper.2005.02.017
61. Zicha J, Kunes J (1999) Ontogenetic aspects of hypertension development: analysis in the rat. Physiol Rev 79:1227–1282